中成药治疗冠状动脉血运重建术后疗效与安全性的系统评价

[目的]系统评价西药加载口服中成药与单纯常规西药治疗冠状动脉血运重建术后患者的临床疗效与安全性。[方法]搜集西药加载口服中成药与常规西药治疗冠状动脉血运重建术后患者的随机对照试验文献,按照Cochrane协作网的方法来评价纳入文献质量和提取有效相关数据进行Meta分析。[结果]共纳入15个研究,包括1 350例患者。结果显示西药加用口服中成药不仅能够改善冠状动脉血运重建术后患者的中医证候疗效、临床总疗效、心绞痛疗效以及心电图疗效,减少冠状动脉再狭窄率,增加心输出量,还能够抑制炎症因子的表达。[结论]西药加载口服中成药较单纯西药治疗冠状动脉血运重建术后患者可进一步提高临床疗效。

A systematic review of the efficacy and safety of Chinese patent medicine in the treatment of coronary revascularization

[Objective] Evaluation of the clinical efficacy and safety of Western medicine in the treatment of postoperative of coronary revascularization with oral proprietary Chinese patent medicine and conventional Western medicine alone.[Methods] A randomized controlled trials were conducted to evaluate the efficacy of Western medicine in the treatment of postoperative of coronary revascularization with oral proprietary Chinese patent medicine and conventional Western medicine. According to the related methods of Cochrane collaboration network, the quality of the literature and the effective correlation Data were Meta analysis.[Results] A total of 15 studies were included, including 1 350 patients. The results showed that Western medicine combined with oral Chinese medicine can not only improve the coronary revascularization in patients with postoperative traditional Chinese medicine syndrome, clinical total curative effect, angina pectoris and ECG curative effect, reduce the restenosis rate, increase cardiac output, but also can inhibit the expression of inflammatory factor.[Conclusion] Compare with Western medicine, Western medicine combine with oral proprietary Chinese patent medicine can be used to treat postoperative of coronary revascularization in patients with acute mycocardial infarction.